Telmisartan (performance-adjacent use)

The verdict

Our read at a glance.

Whether an antihypertensive with metabolic activity does anything for performance, and whether using it to manage drug-induced hypertension is sensible or circular.

The signal

As an antihypertensive the evidence is extensive and the approvals are real, including cardiovascular risk reduction in defined populations, with labelled products and large trial programmes. Its distinguishing pharmacology is genuine: unlike other angiotensin receptor blockers it is a partial agonist at PPAR-gamma, the receptor targeted by the glitazone diabetes drugs, and human and animal work has examined the resulting effects on insulin sensitivity and lipid handling. The endurance claim traces to rodent work showing altered muscle fibre characteristics and running capacity with PPAR pathway activation, and that has not been demonstrated in humans.

The unknown

Whether the PPAR-gamma effect is large enough at antihypertensive doses to matter metabolically in people, and whether any of the rodent endurance findings translate at all.

Our read

The rare case of a genuinely sensible off-label impulse - if a drug is raising your blood pressure, treating the blood pressure is better than ignoring it - wrapped in a performance claim that lives entirely in rodents. Treating a drug-induced problem with a second prescription drug is management, not a solution, and it should involve a doctor who knows about the first drug.